Emergent Biosolutions

Emergent Biosolutions

Yahoo Finance • 14 days ago

Catalyst Watch: Eyes on Walmart, Alibaba, Reddit, and McDonald's energy drink push

[Stock exchange building columns stock market finance] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next we... Full story

Yahoo Finance • 16 days ago

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Vice President and Treasurer - Frank VargoPresident and Chief Executive Officer - Joseph C. Papa Jr.Executive Vice President and Chief Financia... Full story

Yahoo Finance • 21 days ago

Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More

Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in u... Full story

Yahoo Finance • 3 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:... Full story

Yahoo Finance • 4 months ago

Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved

Emergent Biosolutions logo Key Points Emergent says it "significantly progressed" its multi-year turnaround in 2025, reporting a strong adjusted EBITDA of $205 million, a $100 million increase in cash, $110 million of debt reduction, imp... Full story

Yahoo Finance • 4 months ago

Emergent BioSolutions Reports First Quarter 2026 Financial Results

First Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG, Md., April 30... Full story

Yahoo Finance • 5 months ago

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a series of initiatives designed to help increase access to NARCAN® Nasal Spray and encourage the public to be ready to respond... Full story

Yahoo Finance • 5 months ago

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenou... Full story

Yahoo Finance • 6 months ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness byincreasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emer... Full story

Yahoo Finance • 9 months ago

Top European Dividend Stocks For December 2025

As European markets continue to show resilience, with the STOXX Europe 600 Index climbing 2.35% and major single-country indexes also posting gains, investors are increasingly focusing on dividend stocks as a means to generate steady incom... Full story

Yahoo Finance • 10 months ago

Emergent BioSolutions raises 2025 guidance to $835M revenue and $210M EBITDA as international MCM sales surge

Earnings Call Insights: Emergent BioSolutions Inc. (EBS) Q3 2025 MANAGEMENT VIEW * CEO Joseph Papa stated that "we had another great quarter and are on track to exceed our initial 2025 revenue and adjusted EBITDA guidance." He highligh... Full story

Yahoo Finance • 10 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross M... Full story

Yahoo Finance • 11 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 202... Full story

Yahoo Finance • 11 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) today recommitted to i... Full story

Yahoo Finance • 11 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 m... Full story

Yahoo Finance • 11 months ago

Emergent BioSolutions secures $17M contract modification for oral suspension TEMBEXA

* Emergent BioSolutions (NYSE:EBS [https://seekingalpha.com/symbol/EBS]) announced on Monday it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority, part of the Administration... Full story

Yahoo Finance • 11 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), par... Full story

Yahoo Finance • 12 months ago

Mpox in Africa is no longer a global health emergency, WHO chief says

[Blood collection tubes Mpox test positive results,WHO to rename monkeypox as ‘Mpox’] JUN LI The mpox outbreak that originated from Africa last year can no longer be considered a global emergency due to a sustained decline in cases and im... Full story

Yahoo Finance • 12 months ago

Emergent Biosolutions awarded $30 million contract modification for CYFENDUS

* Emergent BioSolutions (NYSE:EBS [https://seekingalpha.com/symbol/EBS]) has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic P... Full story

Yahoo Finance • 12 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), par... Full story